Lyra TherapeuticsLYRA
LYRA
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
8.71% less ownership
Funds ownership: 49.79% [Q3] → 41.08% (-8.71%) [Q4]
11% less funds holding
Funds holding: 62 [Q3] → 55 (-7) [Q4]
34% less capital invested
Capital invested by funds: $8.38M [Q3] → $5.55M (-$2.83M) [Q4]
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$2
1,210%
upside
Avg. target
$2
1,210%
upside
High target
$2
1,210%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
HC Wainwright & Co. Matthew Caufield 43% 1-year accuracy 26 / 61 met price target | 1,210%upside $2 | Neutral Reiterated | 14 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
WATERTOWN, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2024 and provided a corporate update.
Positive
Zacks Investment Research
2 months ago
Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know
Lyra Therapeutics (LYRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Negative
Zacks Investment Research
4 months ago
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.27 per share a year ago.
Neutral
GlobeNewsWire
4 months ago
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the third quarter ended September 30, 2024 and provided a corporate update.
Neutral
GlobeNewsWire
5 months ago
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
-- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN 2 clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled. LYR-210 is a bioresorbable nasal implant designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate) to the sinonasal passages for the treatment of CRS. Topline results from ENLIGHTEN 2 are expected in Q2 2025.
Neutral
GlobeNewsWire
5 months ago
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
WATERTOWN, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the Company will present results from the Phase 3 ENLIGHTEN 1 study for LYR-210, the company's lead product candidate for CRS, at the 70th Annual Meeting of the American Rhinologic Society (ARS), taking place September 27-28 in Miami. The Company will also present additional results from the Phase 2 BEACON study for LYR-220 in adult patients with CRS who have had prior ethmoid sinus surgery at the Annual Meeting of the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), taking place September 28 - October 1 in Miami.
Negative
Zacks Investment Research
7 months ago
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.33 per share a year ago.
Neutral
GlobeNewsWire
7 months ago
Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned –
Neutral
GlobeNewsWire
10 months ago
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
WATERTOWN, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced that it is advancing its goal to preserve capital by implementing a layoff of approximately 75% of its workforce, in addition to other cost-cutting measures.
Negative
InvestorPlace
10 months ago
Why Is Lyra Therapeutics (LYRA) Stock Down 90% Today?
Lyra Therapeutics (NASDAQ: LYRA ) stock is falling hard on Monday after the clinical-stage biotechnology company announced results from a Phase 3 clinical trial of LYR-210. LYR-210 is the company's potential treatment for chronic rhinosinusitis currently in development.
Charts implemented using Lightweight Charts™